14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AMLX vs NTLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 59.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin).
Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (59.8/100 HOLD vs. NTLA 50.7/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AMLX is currently in a Breakdown options structure phase (RSI 46.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published · CRISPR / Gene Editing
Investor FAQ AMLX vs NTLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 59.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin). Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (59.8/100 HOLD vs. NTLA 50.7/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AMLX is currently in a Breakdown options structure phase (RSI 46.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NTLA leads the Growth & Scale pillar: AMLX posts -99.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMLX cumulative revenue shifted +350.0% while NTLA shifted +133.3%. In operating R&D and SG&A reinvestment, AMLX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.
AMLX screens cheaper on headline valuation multiples. AMLX trades at 2.8x Forward P/E, 2.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMLX (-30.1% ROE) versus NTLA (-62.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AMLX carries 61.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.16β · 59% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.